FWP - Forward Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.9680
-0.1320 (-3.20%)
At close: 3:32PM EST
Stock chart is not supported by your current browser
Previous Close1.0000
Open1.0000
Bid0.000 x 100
Ask1.380 x 1000
Day's Range0.8950 - 1.0300
52 Week Range0.8900 - 5.7500
Volume40,345
Avg. Volume45,425
Market Cap45.835M
Beta (3Y Monthly)3.81
PE Ratio (TTM)N/A
EPS (TTM)-0.621
Earnings DateNov 28, 2018 - Dec 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-09-12
1y Target Est37.00
Trade prices are not sourced from all markets
  • Reuters2 months ago

    Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

    The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward. Biogen did not immediately respond to a request for comment. The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment.

  • Reuters2 months ago

    Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

    A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S. The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen from future royalty payments to Forward. Biogen did not immediately respond to a request for comment.

  • GlobeNewswire2 months ago

    Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference

    Forward Pharma A/S (FWP) (“Forward” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has affirmed the decision of the Patent Trial and Appeal Board (the “PTAB”) in the interference proceeding (the “Interference”) between Forward’s U.S. Patent Application No. 11/576,871 (the “’871 application”) and an issued Biogen patent. “We are disappointed with the Federal Circuit’s decision to affirm the decision of the PTAB.  As we have indicated throughout the appeal process, under the Settlement and License Agreement with Biogen, a positive outcome from the Interference after exhaustion of all appeals is among the conditions that must be satisfied for future royalties from the net sales of Tecfidera® in the United States to be payable to Forward,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward.

  • GlobeNewswire3 months ago

    Forward Pharma to Participate in the Ladenburg Thalmann 2018 Healthcare Conference

    Forward Pharma A/S (FWP) (the “Company”) today announced that Dr. Claus Bo Svendsen, the Company’s Chief Executive Officer, will participate in the Ladenburg Thalmann 2018 Healthcare Conference in New York, NY. Dr. Svendsen will present a corporate update on Tuesday, October 2, 2018 at 11:30AM ET and will be available for one-on-one meetings. Investors and other interested parties may access a live audio webcast of Dr. Svendsen’s conference presentation by visiting the investor page on the Company’s website (ir.forward-pharma.com).

  • Benzinga3 months ago

    The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that struck 52-week highs on Sept. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ...

  • GlobeNewswire3 months ago

    Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018

    COPENHAGEN, Denmark, Sept. 19, 2018-- Forward Pharma A/S, today reported consolidated financial results for the six-month period ended June 30, 2018. Net loss for the six-month period ended June 30, 2018 ...

  • ACCESSWIRE7 months ago

    Today's Research Reports on Trending Tickers: Geron and Forward Pharma

    NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...